Idiopathic Hypersomnia and Other Hypersomnia Syndromes.
Idiopathic hypersomnia
Kleine–Levin syndrome
lithium
methylprednisolone
modafinil
psychostimulants
Journal
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
ISSN: 1878-7479
Titre abrégé: Neurotherapeutics
Pays: United States
ID NLM: 101290381
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
10
9
2020
medline:
15
12
2021
entrez:
9
9
2020
Statut:
ppublish
Résumé
There are numerous disorders of known or presumed neurologic origin that result in excessive daytime sleepiness, collectively known as the central disorders of hypersomnolence. These include narcolepsy types 1 and 2, idiopathic hypersomnia, Kleine-Levin syndrome, and hypersomnia due to or associated with medical disease, neurologic disease, psychiatric disease, medications or substances, and insufficient sleep durations. This chapter focuses on the treatment of nonnarcoleptic hypersomnia syndromes, from those that are commonly encountered in neurologic practice, such as hypersomnia due to Parkinson's disease, to those that are exceedingly rare but present with dramatic manifestations, such as Kleine-Levin syndrome. The level of evidence for the treatment of sleepiness in these disorders is generally lower than in the well-characterized syndrome of narcolepsy, but available clinical and randomized, controlled trial data can provide guidance for the management of each of these disorders. Treatments vary by diagnosis but may include modafinil/armodafinil, traditional psychostimulants, solriamfetol, pitolisant, clarithromycin, flumazenil, sodium oxybate, melatonin, methylprednisolone, and lithium.
Identifiants
pubmed: 32901432
doi: 10.1007/s13311-020-00919-1
pii: 10.1007/s13311-020-00919-1
pmc: PMC8116415
doi:
Substances chimiques
Central Nervous System Stimulants
0
Wakefulness-Promoting Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-31Subventions
Organisme : NINDS NIH HHS
ID : R01 NS111280
Pays : United States
Références
Trotti LM. Waking up is the hardest thing I do all day: Sleep inertia and sleep drunkenness. Sleep Med Rev 2016.
Maness C, Saini P, Bliwise DL, Olvera V, Rye DB, Trotti LM. Systemic exertion intolerance disease/chronic fatigue syndrome is common in sleep centre patients with hypersomnolence: A retrospective pilot study. J Sleep Res 2018;e12689.
Vernet C, Leu-Semenescu S, Buzare MA, Arnulf I. Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness. J Sleep Res 2010;19:525-534.
pubmed: 20408941
Miglis MG, Schneider L, Kim P, Cheung J, Trotti LM. Frequency and Severity of Autonomic Symptoms in Idiopathic Hypersomnia. J Clin Sleep Med 2020.
International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine 2014.
Vernet C, Arnulf I. Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients. Sleep 2009;32:753-759.
pubmed: 19544751
pmcid: 2690562
Evangelista E, Lopez R, Barateau L, et al. Alternative diagnostic criteria for idiopathic hypersomnia: A 32-hour protocol. Ann Neurol 2018;83:235-247.
pubmed: 29323727
Pizza F, Moghadam KK, Vandi S, et al. Daytime continuous polysomnography predicts MSLT results in hypersomnias of central origin. J Sleep Res 2013;22:32-40.
pubmed: 22716477
Ohayon MM, Reynolds CF, 3rd, Dauvilliers Y. Excessive sleep duration and quality of life. Ann Neurol 2013;73:785-794.
pubmed: 23846792
pmcid: 4142503
Rye DB, Bliwise DL, Parker K, et al. Modulation of Vigilance in the Primary Hypersomnias by Endogenous Enhancement of GABAA Receptors. Sci Transl Med 2012;4:161ra51.
Landzberg D, Trotti LM. Is Idiopathic Hypersomnia a Circadian Rhythm Disorder? Current Sleep Medicine Reports 2019;5:201-206.
pubmed: 33312847
pmcid: 7731890
Boucetta S, Montplaisir J, Zadra A, et al. Altered Regional Cerebral Blood Flow in Idiopathic Hypersomnia. Sleep 2017;40.
Pomares FB, Boucetta S, Lachapelle F, et al. Beyond sleepy: structural and functional changes of the default-mode network in idiopathic hypersomnia. Sleep 2019.
Sforza E, Roche F, Barthelemy JC, Pichot V. Diurnal and nocturnal cardiovascular variability and heart rate arousal response in idiopathic hypersomnia. Sleep Med 2016;24:131-136.
pubmed: 27810179
Fronczek R, Arnulf I, Baumann CR, Maski K, Pizza F, Trotti LM. To Split or to Lump? Classifying the Central Disorders of Hypersomnolence. Sleep 2020.
Murillo-Rodriguez E, Barciela Veras A, Barbosa Rocha N, Budde H, Machado S. An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil. ACS Chem Neurosci 2018;9:151-158.
pubmed: 29115823
Mayer G, Benes H, Young P, Bitterlich M, Rodenbeck A. Modafinil in the treatment of idiopathic hypersomnia without long sleep time-a randomized, double-blind, placebo-controlled study. J Sleep Res 2015;24:74-81.
pubmed: 25196321
Philip P, Chaufton C, Taillard J, et al. Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial. Sleep 2014;37:483-487.
pubmed: 24587570
pmcid: 3920313
Sagaspe P, Micoulaud-Franchi JA, Coste O, et al. Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia. Sleep Med 2019;55:1-5.
pubmed: 30735912
Inoue Y, Hirata K. The effectiveness of modafinil for the treatment of idiopathic hypersomnia. Sleep 2017;40:A250-A1.
Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1988;12:695-700.
Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM. Idiopathic hypersomnia: a study of 77 cases. Sleep 2007;30:1274-1281.
pubmed: 17969461
pmcid: 2266276
Ali M, Auger RR, Slocumb NL, Morgenthaler T. Idiopathic hypersomnia: clinical features and response to treatment. J Clin Sleep Med 2009;5:562-568.
pubmed: 20465024
pmcid: 2792973
Lavault S, Dauvilliers Y, Drouot X, et al. Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med 2011;12:550-556.
pubmed: 21576035
Schwartz JR, Feldman NT, Bogan RK. Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. The Journal of Neuropsychiatry and Clinical Neurosciences 2005;17:405-412.
pubmed: 16179665
Modafinil package insert. 2004; Available from: https://www.modafinil.com/prescribe/index.html .
Reymond D. Alertec (modafinil) and the risk of congenital anomalies. Government of Canada/Health Canada; 2019 [10/30/2019]; Available from: https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70201a-eng.php .
Damkier P, Broe A. First-Trimester Pregnancy Exposure to Modafinil and Risk of Congenital Malformations. JAMA 2020;323:374-376.
pubmed: 31990303
pmcid: 6990936
Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705-1711.
pubmed: 18246980
pmcid: 2276123
Adderall package insert. 2007; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf .
Sunosi (solriamfetol) package insert. 2019; Available from: https://sunosihcp.com .
Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3): A Randomized Controlled Trial. Am J Respir Crit Care Med 2019;199:1421-1431.
pubmed: 30521757
pmcid: 6835071
Thorpy MJ, Shapiro C, Mayer G, et al. A Randomized Study of Solriamfetol for Excessive Sleepiness in Narcolepsy. Ann Neurol 2019;85:359-370.
pubmed: 30694576
pmcid: 6593450
Leu-Semenescu S, Nittur N, Golmard JL, Arnulf I. Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. Sleep Med 2014;15:681-687.
pubmed: 24854887
Robert P, Schwartz J-C. Hormonal Contraceptive and Pitolisant CYP3A4 Induction. Neurology. 2019;92:P3.6-035.
Wakix (pitolisant) package insert. 2019; Available from: https://wakix.com .
Bichler EK, Elder CC, Garcia PS. Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling. J Neurophysiol 2017;117:93-103.
pubmed: 27733592
Garcia PS, Jenkins A, editors. Inhibition of the GABA(A) receptor by a macrolide but not by a lincosamide antibiotic. Proceedings of the 2009 Annual Meeting of the American Society of Anesthesiologists 2009.
Trotti LM, Saini P, Bliwise DL, Freeman AA, Jenkins A, Rye DB. Clarithromycin in gamma-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. Ann Neurol 2015;78:454-465.
pubmed: 26094838
pmcid: 4732573
Winkel P, Hilden J, Hansen JF, et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol 2015;182:459-465.
pubmed: 25602299
Clarithromycin Full Prescribing Information (package insert). Updated 1/2019.
Trotti LM, Saini P, Koola C, LaBarbera V, Bliwise DL, Rye DB. Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients. J Clin Sleep Med 2016;12:1389-1394.
pubmed: 27568889
pmcid: 5033741
Kelty E, Martyn V, O'Neil G, Hulse G. Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report. J Psychopharmacol 2014.
Takei Y, Komada Y, Namba K, et al. Differences in findings of nocturnal polysomnography and multiple sleep latency test between narcolepsy and idiopathic hypersomnia. Clin Neurophysiol 2012;123:137-141.
pubmed: 21723190
Tassi P, Muzet A. Sleep inertia. Sleep Med Rev 2000;4:341-353.
pubmed: 12531174
Leu-Semenescu S, Louis P, Arnulf I. Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review. Sleep Med 2016;17:38-44.
pubmed: 26847972
Vernet C, Arnulf I. Narcolepsy with long sleep time: a specific entity? Sleep 2009;32:1229-1235.
pubmed: 19750928
pmcid: 2737581
Thomann J, Baumann CR, Landolt HP, Werth E. Psychomotor vigilance task demonstrates impaired vigilance in disorders with excessive daytime sleepiness. J Clin Sleep Med 2014;10:1019-1024.
pubmed: 25142762
pmcid: 4153121
Ramm M, Boentert M, Lojewsky N, Jafarpour A, Young P, Heidbreder A. Disease-specific attention impairment in disorders of chronic excessive daytime sleepiness. Sleep Med 2018;53:133-140.
pubmed: 30508781
Arnulf I. Excessive daytime sleepiness and parkinsonism. Sleep Med Rev 2005;9:185-200.
pubmed: 15893249
Ghergan A, Coupaye M, Leu-Semenescu S, et al. Prevalence and Phenotype of Sleep Disorders in 60 Adults With Prader-Willi Syndrome. Sleep 2017;40:doi: https://doi.org/10.1093/sleep/zsx162 .
Pépin J, Viot-Blanc V, Escourrou P, et al. Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Resp J 2009;33:1062-1067.
Vernet C, Redolfi S, Attali V, et al. Residual sleepiness in obstructive sleep apnoea: phenotype and related symptoms. Eur Respir J 2011;38:98-105.
pubmed: 21406511
Imbach LL, Valko PO, Li T, et al. Increased sleep need and daytime sleepiness 6 months after traumatic brain injury: a prospective controlled clinical trial. Brain 2015;138:726-735.
pubmed: 25595147
pmcid: 4408434
Valko PO, Gavrilov YV, Yamamoto M, et al. Damage to histaminergic tuberomammillary neurons and other hypothalamic neurons with traumatic brain injury. Annals of Neurology 2015;77:177-182.
pubmed: 25363332
Kingshott RN, Vennelle M, Coleman EL, Engleman HM, Mackay TW, Douglas NJ. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001;163:918-923.
pubmed: 11282766
Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clinical Therapeutics 2006;28:689-706.
pubmed: 16861091
Sheng P, Hou L, Wang X, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One 2013;8:e81802.
pubmed: 24312590
pmcid: 3849275
Trotti LM, Bliwise DL. Treatment of the sleep disorders associated with Parkinson’s disease. Neurotherapeutics 2014;11:68-77.
pubmed: 24272458
Buchele F, Hackius M, Schreglmann SR, et al. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology 2018;75:114-118.
pubmed: 29114733
Kaiser PR, Valko PO, Werth E, et al. Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology 2010;75:1780-1785.
pubmed: 21079179
Jha A, Weintraub A, Allshouse A, et al. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma Rehabil 2008;23:52-63.
pubmed: 18219235
Menn SJ, Yang R, Lankford A. Armodafinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: a 12-week, randomized, double-blind study followed by a 12-month open-label extension. J Clin Sleep Med 2014;10:1181-1191.
pubmed: 25325609
pmcid: 4224718
Annane D, Moore DH, Barnes PR, Miller RG. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. Cochrane Database Syst Rev 2006;CD003218.
Plante DT. Sleep propensity in psychiatric hypersomnolence: A systematic review and meta-analysis of multiple sleep latency test findings. Sleep Med Rev 2017;31:48-57.
pubmed: 26883161
Vgontzas AN, Bixler EO, Kales A, Criley C, Vela-Bueno A. Differences in nocturnal and daytime sleep between primary and psychiatric hypersomnia: diagnostic and treatment implications. Psychosom Med 2000;62:220-226.
pubmed: 10772401
Plante DT, Cook JD, Goldstein MR. Objective measures of sleep duration and continuity in major depressive disorder with comorbid hypersomnolence: a primary investigation with contiguous systematic review and meta-analysis. J Sleep Res 2017;26:255-265.
pubmed: 28145043
pmcid: 5435536
Plante DT, Birn RM, Walsh EC, Hoks RM, Cornejo MD, Abercrombie HC. Reduced resting-state thalamostriatal functional connectivity is associated with excessive daytime sleepiness in persons with and without depressive disorders. J Affect Disord 2018;227:517-520.
pubmed: 29161673
Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2007;27:614-619.
pubmed: 18004129
DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR, Modafinil in Depression Study G. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:1057-1064.
pubmed: 14628981
Arnulf I, Rico T, Mignot E. Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. Lancet Neurol 2012;11:918-928.
pubmed: 22995695
Dauvilliers Y, Mayer G, Lecendreux M, et al. Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses. Neurology 2002;59:1739-1745.
pubmed: 12473762
Arnulf I, Lin L, Gadoth N, et al. Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol 2008;63:482-493.
pubmed: 18438947
Huang Y, Guilleminault C, Lin K, Hwang F, Liu F, Kung Y. Relationship between Kleine-Levin Syndrome and upper respiratory Infection in Taiwan. Sleep 2012;35:123-129.
pubmed: 22215926
pmcid: 3242678
Lavault S, Golmard J, Groos E, et al. Kleine-Levin syndrome in 120 patients: Differential diagnosis and long episodes. Annals of Neurology 2015;77:529-540.
pubmed: 25559212
Wang JY, Han F, Dong SX, et al. Cerebrospinal fluid orexin A levels and autonomic function in Kleine-Levin syndrome. Sleep 2016;39:855-860.
pubmed: 26943469
pmcid: 4791619
Kas A, Lavault S, Habert MO, Arnulf I. Feeling unreal: a functional imaging study in 41 patients with Kleine-Levin syndrome. Brain 2014;137:2077-2087.
pubmed: 24785943
Hegarty A, Merriam AE. Autonomic events in Kleine-Levin syndrome. Am J Psychiatry 1990;147:951-952.
pubmed: 2356886
Arnulf I, Zeitzer JM, File J, Farber N, Mignot E. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain 2005;128:2763-2776.
pubmed: 16230322
Gadoth N, Kesler A, Vainstein G, Peled R, Lavie P. Clinical and polysomnographic characteristics of 34 patients with Kleine-Levin syndrome. J Sleep Res 2001;10:337-341.
pubmed: 11903864
Huang Y, Lin Y, Guilleminault C. Polysomnography in Kleine-Levin syndrome. Neurology 2008;70:795-801.
pubmed: 18316691
Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-1562.
pubmed: 12374492
Uguccioni G, Lavault S, Chaumereuil C, Golmard JL, Gagnon JF, Arnulf I. Long-term cognitive impairment in Kleine-Levin syndrome. Sleep 2015;39:429-438.
Groos E, Chaumereuil C, Flamand M, et al. Emerging psychiatric disorders in Kleine-Levin syndrome. J Sleep Res 2018;27:e12690.
pubmed: 29655261
Huang YS, Guilleminault C, Kao PF, Liu FY. SPECT findings in the Kleine-Levin syndrome. Sleep 2005;28:955-960.
pubmed: 16218078
Carpenter S, Yassa R, Ochs R. A pathologic basis for Kleine-Levin syndrome. Arch Neurol 1982;39:25-28.
pubmed: 6948538
Koerber RK, Torkelson R, Haven G, Donaldson J, Cohen SM, Case M. Increased cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in Kleine-Levin syndrome. Neurology 1984;34:1597-1600.
pubmed: 6209595
Takrani LB, Cronin D. Kleine-Levin syndrome in a female patient. Can Psychiatr Assoc J 1976;21:315-318.
pubmed: 991067
Fenzi F, Simonati A, Crosato F, Ghersini L, Rizzuto N. Clinical features of Kleine-Levin syndrome with localized encephalitis. Neuropediatrics 1993;24:292-295.
pubmed: 8309520
Kornum B, Rico T, Lin L, et al. Serum cytokine levels in Kleine-Levin syndrome. Sleep Medicine 2015;16:961-965.
pubmed: 26116465
Bahammam A, Gadelrab M, Owais S, Alswat K, Hamam K. Clinical characteristics and HLA typing of a family with Kleine-Levin syndrome. Sleep medicine 2008;9:575-578.
pubmed: 17761456
Nguyen Q, Groos E, Leclair-Visonneau L, et al. Familial Kleine-Levin syndrome. Sleep 2016;39:1535-1542.
pubmed: 27253765
pmcid: 4945312
Ambati A, Hillary R, Semenescu SL, Lin L, Ollila H, Farber N, Huang Y, Dauvilliers Y, KLS Working Group, Arnulf I, Mignot E. Strong Gene-Environment Interactions of Trank1 Gene Polymorphisms with Birth Difficulties in Kleine Levin Syndrome. Sleep, 2020;43(Suppl 1):A10-A11
Leotard A, Groos E, Chaumereuil C, et al. IV steroids during long episodes of Kleine-Levin syndrome. Neurology 2018;90:e1488-e1492.
pubmed: 29572278
Rezvanian E, Watson NF. Kleine-levin syndrome treated with clarithromycin. J Clin Sleep Med 2013;9:1211-1212.
pubmed: 24235906
pmcid: 3805810
Trotti LM, Bliwise DL, Rye DB. Further Experience using Clarithromycin in Patients with Kleine-Levin Syndrome. J Clin Sleep Med 2014;10:457-458.
pubmed: 24733995
pmcid: 3960392
Leu-Semenescu S, Le Corvec T, Groos E, Lavault S, Golmard JL, Arnulf I. Lithium therapy in Kleine-Levin syndrome: an open-label, controlled study in 130 patients. Neurology 2015;85:1655-1662.
pubmed: 26453648
Billiard M, Guilleminault C, Dement WC. A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or new clinical entity? Neurology 1975;25:436-443.
pubmed: 166331